Recent Updates
Recently added Catalysts
TLX Negative Sentiment

Telix Pharmaceuticals Ltd. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights – TLX

Key Takeaway: Telix Pharmaceuticals Ltd. is currently facing a class action lawsuit filed by Levi & Korsinsky, LLP for alleged securities law violations. The lawsuit targets investors affected by purported securities fraud between February 21 and August 28, 2025. It claims that the company's executives made misleading statements regarding the progress of their prostate cancer treatments and the quality of their supply chain. Affected investors have until January 9, 2026, to participate as lead plaintiffs in the case.
Price reaction · baseline $9.04 (2025-11-19 close) · hit after-hours · 6 other TLX headline(s) in the window, move may be shared
day 0 close · peak
-3%

Market Sentiment Analysis

CONCERNS & RISKS

  • Telix Pharmaceuticals Ltd. faces a class action securities lawsuit for alleged fraud.
  • The lawsuit claims the company overstated its progress in prostate cancer therapeutic candidates.
  • Concerns about the quality of Telix's supply chain and partnerships were allegedly concealed.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7%
average across 7 past catalysts
Lead asset
131I-IPA
Phase 1 · Neoplastic Disease

Full Press Release Details

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team:
TLX investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) defendants materially overstated the quality of Telix’s supply chain and partners; and (3) as a result, defendants’ statements about Telix’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
WHAT'S NEXT? If you suffered a loss in Telix Pharmaceuticals Ltd. during the relevant time frame, you have until January 9, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor

Frequently Asked Questions

What is the Telix Pharmaceuticals lawsuit about?

The lawsuit concerns alleged securities fraud affecting investors between February 21, 2025, and August 28, 2025.

What are the claims made in the Telix lawsuit?

Plaintiffs claim that Telix misrepresented its progress in prostate cancer therapies and quality of its supply chain.

What is the deadline to join the Telix lawsuit?

Investors have until January 9, 2026, to request lead plaintiff status.

Is there a cost to participate in the lawsuit?

No, class members may be eligible for compensation without any out-of-pocket costs.

Why choose Levi & Korsinsky for this lawsuit?

The firm has over 20 years of experience with a strong track record in securities litigation.

Last updated: Nov 20, 2025